Skip to main content
Top
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Primary research

Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer

Authors: Wenjing Zhu, Qiliang Zhang, Min Liu, Meixing Yan, Xiao Chu, Yongchun Li

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Background

Liver cancer (LC) is one of the most fatal cancers throughout the world. More efficient and sensitive gene signatures that could accurately predict survival in LC patients are vitally needed to promote a better individualized and effective treatment.

Material/methods

422 LC and adjacent normal tissues with both RNA-Seq and clinical data in TCGA were embedded in our study. Gene set enrichment analysis (GSEA) was applied to identify genes and hallmark gene sets that are more valuable for liver cancer therapy. Cox regression analysis was used to identify genes related to overall survival (OS) and build the prediction model. cBioPortal database was used to examine the alterations of the panel mRNA signature. ROC curves and Kaplan–Meier curves were used to validate the prediction model. Besides, the expression of the genes in the model were validated using quantitative real-time PCR in clinical tissue specimens.

Results

The panel of DNA repair-related mRNA signature consisted of seven mRNAs: RFC4 (replication factor C subunit 4), ZWINT (ZW10 interacting kinetochore protein), UPF3B (UPF3B regulator of nonsense mediated mRNA decay), NCBP2 (nuclear cap binding protein subunit 2), ADA (adenosine deaminase), SF3A3 (splicing factor 3a subunit 3) and GTF2H1 (general transcription factor IIH subunit 1). On-line analysis of cBioPortal database found that the expression of the panel mRNA has a wide variation ranging from 7 to 10%. All the mRNAs were significantly upregulated in LC tissues compared to normal tissues (P < 0.05). The risk model is closely related to the OS of LC patients. The hazard ratio (HR) is 2.184 [95% CI (confidence interval) 1.523–3.132] and log-rank P-value < 0.0001. For clinical specimen validation, we found that all of the genes in the model upregulated in liver cancer tissues versus normal liver tissues, which was consistent with the results predicted.

Conclusions

Our study demonstrated a mRNA signature including seven mRNA for prognosis prediction of LC. This panel gene signature provides a new criterion for accurate diagnosis and therapeutic target of LC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed
2.
go back to reference Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMed Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMed
3.
go back to reference Bai L, Liu Z, Fang Q, et al. The trends and projections in the incidence and mortality of liver cancer in urban Shanghai: a population-based study from 1973 to 2020. Clin Epidemiol. 2018;10:277–88.CrossRefPubMedPubMedCentral Bai L, Liu Z, Fang Q, et al. The trends and projections in the incidence and mortality of liver cancer in urban Shanghai: a population-based study from 1973 to 2020. Clin Epidemiol. 2018;10:277–88.CrossRefPubMedPubMedCentral
4.
go back to reference Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–9.CrossRefPubMed Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–9.CrossRefPubMed
6.
go back to reference Kitao H, Iimori M, Kataoka Y, et al. DNA replication stress and cancer chemotherapy. Cancer Sci. 2018;109(2):264–71.CrossRefPubMed Kitao H, Iimori M, Kataoka Y, et al. DNA replication stress and cancer chemotherapy. Cancer Sci. 2018;109(2):264–71.CrossRefPubMed
7.
go back to reference Stiuso P, Potenza N, Lombardi A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 2015;4:e233.CrossRefPubMed Stiuso P, Potenza N, Lombardi A, et al. MicroRNA-423-5p promotes autophagy in cancer cells and is increased in serum from hepatocarcinoma patients treated with sorafenib. Mol Ther Nucleic Acids. 2015;4:e233.CrossRefPubMed
8.
go back to reference Caraglia M, Giuberti G, Marra M, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2(4):e150.CrossRefPubMedPubMedCentral Caraglia M, Giuberti G, Marra M, et al. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2(4):e150.CrossRefPubMedPubMedCentral
9.
go back to reference Lombardi A, Grimaldi A, Zappavigna S, et al. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol. 2018;64(1):14–27.PubMed Lombardi A, Grimaldi A, Zappavigna S, et al. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol. 2018;64(1):14–27.PubMed
11.
go back to reference Chang WH, Lai AG. Transcriptional landscape of DNA repair genes underpins a pan-cancer prognostic signature associated with cell cycle dysregulation and tumor hypoxia. DNA Repair (Amst). 2019;78:142–53.CrossRef Chang WH, Lai AG. Transcriptional landscape of DNA repair genes underpins a pan-cancer prognostic signature associated with cell cycle dysregulation and tumor hypoxia. DNA Repair (Amst). 2019;78:142–53.CrossRef
12.
go back to reference Tolan HK, Tozan-Beceren A, Sardas S, et al. DNA repair capacity of the colorectal cancer patients and the correlation between the pathological parameters. Niger J Clin Pract. 2019;22(2):194–200.PubMed Tolan HK, Tozan-Beceren A, Sardas S, et al. DNA repair capacity of the colorectal cancer patients and the correlation between the pathological parameters. Niger J Clin Pract. 2019;22(2):194–200.PubMed
14.
go back to reference Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol. 2019;145:1471–84.CrossRefPubMed Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol. 2019;145:1471–84.CrossRefPubMed
15.
go back to reference Lopez-Camarillo C, Rincon DG, Ruiz-Garcia E, et al. DNA repair proteins as therapeutic targets in ovarian cancer. Curr Protein Pept Sci. 2019;20(4):316–23.CrossRefPubMed Lopez-Camarillo C, Rincon DG, Ruiz-Garcia E, et al. DNA repair proteins as therapeutic targets in ovarian cancer. Curr Protein Pept Sci. 2019;20(4):316–23.CrossRefPubMed
16.
go back to reference Wang R, Ye XH, Zhao XL, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma. 2018;66:343–9.CrossRefPubMed Wang R, Ye XH, Zhao XL, et al. Development of a five-gene signature as a novel prognostic marker in ovarian cancer. Neoplasma. 2018;66:343–9.CrossRefPubMed
18.
go back to reference Wei H, Li J, Xie M, et al. Comprehensive analysis of metastasis-related genes reveals a gene signature predicting the survival of colon cancer patients. PeerJ. 2018;6:e5433.CrossRefPubMedPubMedCentral Wei H, Li J, Xie M, et al. Comprehensive analysis of metastasis-related genes reveals a gene signature predicting the survival of colon cancer patients. PeerJ. 2018;6:e5433.CrossRefPubMedPubMedCentral
19.
go back to reference Kim K, Jeon S, Kim TM, et al. Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers. 2018;10(12):494.CrossRefPubMedCentral Kim K, Jeon S, Kim TM, et al. Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers. 2018;10(12):494.CrossRefPubMedCentral
20.
go back to reference Cai W, Li Y, Huang B, et al. Esophageal cancer lymph node metastasis-associated gene signature optimizes overall survival prediction of esophageal cancer. J Cell Biochem. 2019;120(1):592–600.CrossRefPubMed Cai W, Li Y, Huang B, et al. Esophageal cancer lymph node metastasis-associated gene signature optimizes overall survival prediction of esophageal cancer. J Cell Biochem. 2019;120(1):592–600.CrossRefPubMed
21.
go back to reference Zuo S, Dai G, Ren X. Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell Int. 2019;19(6):1–15. Zuo S, Dai G, Ren X. Identification of a 6-gene signature predicting prognosis for colorectal cancer. Cancer Cell Int. 2019;19(6):1–15.
22.
go back to reference Sun LL, Wu JY, Wu ZY, et al. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer. 2015;136(6):E569–77.CrossRefPubMed Sun LL, Wu JY, Wu ZY, et al. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer. 2015;136(6):E569–77.CrossRefPubMed
23.
go back to reference Gold B. Somatic mutations in cancer: Stochastic versus predictable. Mutat Res. 2017;814:37–46.CrossRef Gold B. Somatic mutations in cancer: Stochastic versus predictable. Mutat Res. 2017;814:37–46.CrossRef
24.
go back to reference Perduca V, Alexandrov LB, Kelly-Irving M, et al. Stem cell replication, somatic mutations and role of randomness in the development of cancer. Eur J Epidemiol. 2019;34(5):439–45.CrossRefPubMed Perduca V, Alexandrov LB, Kelly-Irving M, et al. Stem cell replication, somatic mutations and role of randomness in the development of cancer. Eur J Epidemiol. 2019;34(5):439–45.CrossRefPubMed
25.
go back to reference Nakajima Y, Kuribayashi K. Adenosine deaminase in pleural effusion and its relationship with clinical parameters in patients with malignant pleural mesothelioma. Cancer Investig. 2020;38(6):356–64.CrossRef Nakajima Y, Kuribayashi K. Adenosine deaminase in pleural effusion and its relationship with clinical parameters in patients with malignant pleural mesothelioma. Cancer Investig. 2020;38(6):356–64.CrossRef
26.
go back to reference Kong J, Wang T, Zhang Z, et al. Five core genes related to the progression and prognosis of hepatocellular carcinoma identified by analysis of a coexpression network. DNA Cell Biol. 2019;38(12):1564–76.CrossRefPubMed Kong J, Wang T, Zhang Z, et al. Five core genes related to the progression and prognosis of hepatocellular carcinoma identified by analysis of a coexpression network. DNA Cell Biol. 2019;38(12):1564–76.CrossRefPubMed
27.
go back to reference Xiang J, Fang L, Luo Y, et al. Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. J Transl Med. 2014;12:320.CrossRefPubMedPubMedCentral Xiang J, Fang L, Luo Y, et al. Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer. J Transl Med. 2014;12:320.CrossRefPubMedPubMedCentral
28.
go back to reference Ying H, Xu Z, Chen M, et al. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther. 2018;11:689–702.CrossRefPubMedPubMedCentral Ying H, Xu Z, Chen M, et al. Overexpression of Zwint predicts poor prognosis and promotes the proliferation of hepatocellular carcinoma by regulating cell-cycle-related proteins. Onco Targets Ther. 2018;11:689–702.CrossRefPubMedPubMedCentral
29.
go back to reference Li N, Zhao L, Guo C, et al. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res. 2019;11:7473–84.CrossRefPubMedPubMedCentral Li N, Zhao L, Guo C, et al. Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma. Cancer Manag Res. 2019;11:7473–84.CrossRefPubMedPubMedCentral
30.
go back to reference Wu W, Liu H, Lei R, et al. Genetic variants in GTF2H1 and risk of lung cancer: a case-control analysis in a Chinese population. Lung Cancer. 2009;63(2):180–6.CrossRefPubMed Wu W, Liu H, Lei R, et al. Genetic variants in GTF2H1 and risk of lung cancer: a case-control analysis in a Chinese population. Lung Cancer. 2009;63(2):180–6.CrossRefPubMed
31.
go back to reference Nastase A, Lupo A, Laszlo V, et al. Platinum drug sensitivity polymorphisms in stage III non-small cell lung cancer with invasion of mediastinal lymph nodes. Cancer Genomics Proteomics. 2020;17(5):587–95.CrossRefPubMedPubMedCentral Nastase A, Lupo A, Laszlo V, et al. Platinum drug sensitivity polymorphisms in stage III non-small cell lung cancer with invasion of mediastinal lymph nodes. Cancer Genomics Proteomics. 2020;17(5):587–95.CrossRefPubMedPubMedCentral
32.
go back to reference Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II SoLAR study. Cancer Chemother Pharmacol. 2010;66(5):837–44.CrossRefPubMed Prete SD, Montella L, Caraglia M, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II SoLAR study. Cancer Chemother Pharmacol. 2010;66(5):837–44.CrossRefPubMed
33.
go back to reference Itzel T, Spang R, Maass T, et al. Random gene sets in predicting survival of patients with hepatocellular carcinoma. J Mol Med (Berl). 2019;97(6):879–88.CrossRef Itzel T, Spang R, Maass T, et al. Random gene sets in predicting survival of patients with hepatocellular carcinoma. J Mol Med (Berl). 2019;97(6):879–88.CrossRef
34.
go back to reference Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–76.CrossRefPubMed Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–76.CrossRefPubMed
35.
go back to reference Poulos RC, Wong YT, Ryan R. Analysis of 7815 cancer exomes reveals associations between mutational processes and somatic driver mutations. PLoS Genet. 2018;14(11):e1007779.CrossRefPubMedPubMedCentral Poulos RC, Wong YT, Ryan R. Analysis of 7815 cancer exomes reveals associations between mutational processes and somatic driver mutations. PLoS Genet. 2018;14(11):e1007779.CrossRefPubMedPubMedCentral
36.
go back to reference Levine AJ, Puzio-Kuter AM, Chan CS, et al. The role of the p53 protein in stem-cell biology and epigenetic regulation. Cold Spring Harb Perspect Med. 2016;6(9):a026153.CrossRefPubMedPubMedCentral Levine AJ, Puzio-Kuter AM, Chan CS, et al. The role of the p53 protein in stem-cell biology and epigenetic regulation. Cold Spring Harb Perspect Med. 2016;6(9):a026153.CrossRefPubMedPubMedCentral
37.
go back to reference Herath NI, Devun F, Lienafa MC, et al. The DNA repair inhibitor DT01 as a novel therapeutic strategy for chemosensitization of colorectal liver metastasis. Mol Cancer Ther. 2016;15(1):15–22.CrossRefPubMed Herath NI, Devun F, Lienafa MC, et al. The DNA repair inhibitor DT01 as a novel therapeutic strategy for chemosensitization of colorectal liver metastasis. Mol Cancer Ther. 2016;15(1):15–22.CrossRefPubMed
38.
go back to reference Yan J, Zhou C, Guo K, et al. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem. 2019;120(1):213–23.CrossRefPubMed Yan J, Zhou C, Guo K, et al. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. J Cell Biochem. 2019;120(1):213–23.CrossRefPubMed
39.
go back to reference Kancherla V, Abdullazade S, Matter MS, et al. Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma. Front Genet. 2018;9:2.CrossRefPubMedPubMedCentral Kancherla V, Abdullazade S, Matter MS, et al. Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma. Front Genet. 2018;9:2.CrossRefPubMedPubMedCentral
Metadata
Title
Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer
Authors
Wenjing Zhu
Qiliang Zhang
Min Liu
Meixing Yan
Xiao Chu
Yongchun Li
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-01779-1

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine